First Manhattan’s Trevi Therapeutics TRVI Stock Holding History

First Manhattan’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500	Closed	-$965	–	1704
2022 Q4	$965	Sell	500 -1,000	-67%	-$1.97K	﹤0.01%	1583
2022 Q3	$2K	Sell	1,500 -1,000	-40%	-$3.28K	﹤0.01%	1435
2022 Q2	$7K	Hold	2,500	–	–	﹤0.01%	1293
2022 Q1	$5K	Sell	2,500 -1,000	-29%	-$1.04K	﹤0.01%	1392
2021 Q4	$2K	Hold	3,500	–	–	﹤0.01%	1492
2021 Q3	$4K	Hold	3,500	–	–	﹤0.01%	1450
2021 Q2	$7K	Buy	3,500 +1,600	+84%	+$3.6K	﹤0.01%	1343
2021 Q1	$5K	Sell	1,900 -100	-5%	-$293	﹤0.01%	1347
2020 Q4	$4K	Buy	2,000 +1,000	+100%	+$3.24K	﹤0.01%	1237
2020 Q3	$4K	Buy	+1,000	New	+$4.7K	﹤0.01%	1223

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

First Manhattan's TRVI Position: Q1 2023 in Review

First Manhattan sold out of Trevi Therapeutics (TRVI) in Q1 2023, closing a stake of 500 shares — an estimated $965 sold.

First Manhattan first reported a position in TRVI in Q3 2020 and held it in 10 quarters. The position peaked at $7K in Q2 2022. 36 funds tracked by Wall St. Rank hold TRVI as of Q1 2023.

First Manhattan reported no remaining Trevi Therapeutics position as of Q1 2023 after selling out during the quarter.
First Manhattan sold 500 Trevi Therapeutics shares in Q1 2023, an estimated $965.
First Manhattan first reported a position in Trevi Therapeutics in Q3 2020 and held it in 10 quarters.
First Manhattan's Trevi Therapeutics position peaked at $7K in Q2 2022.
36 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.